Keep checking for updates and new content.

Treatments

Video: “Partial gland ablation for localized prostate cancer: Who is eligible and what are the risks?”

August 16, 2017

July 2017 Awareness Night Partial gland ablation for localized prostate cancer: Who is eligible and what are the risks? Dr. Nathan Perlis, MD, MSc, FRCSC Clinical assistant, Division of Urology, University Health Network Clinical fellow, Society of Urological Oncology, University of Toronto     CLICK ON THE ARROW TO START THE VIDEO The Complete Presentation […]

Read the article or watch the video →

Video: Active Surveillance: Protecting Patients from Harm – Dr. Laurence Klotz

August 2, 2017

From a conference in May 2017, a comprehensive overview of active surveillance by one of the experts in the field. View video.

Read the article or watch the video →

Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival

July 2, 2017

Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer worsened, from 14.8 months to 33 months. Read the […]

Read the article or watch the video →

Immunotherapy

July 2, 2017

Immunotherapy is an exciting new field of study that is designed to boost the body’s immune system to fight cancer. It uses materials either made by the body or in a lab to improve, target or restore immune function. There are different types of immunotherapy including vaccines, monoclonal antibodies and non-specific immunotherapies. In prostate cancer, […]

Read the article or watch the video →

Single-fraction, high-dose brachytherapy may be viable for localized prostate cancer

July 2, 2017

Single-fraction 19 Gy high dose–rate brachytherapy may be a safe and effective treatment alternative for men with localized prostate cancer, according to study results. Read the article here.

Read the article or watch the video →

Active Surveillance in Men under 60

July 2, 2017

Younger age at diagnosis of low-risk prostate cancer was independently associated with decreased risk of disease progression in men managed with active surveillance, researchers reported. Read the article here. Active surveillance is a reasonable option for carefully selected men under 60 with low-risk prostate cancer. However, patients must be surveyed closely and understand the significant […]

Read the article or watch the video →

Active Surveillance for Prostate Cancer: How to Do It Right

July 2, 2017

Active surveillance should be offered to patients with a low risk of cancer progression, including those with a life expectancy of more than 10 years, clinical stage T1/2a disease, a PSA level < 15 ng/mL, and biopsy Gleason score of ≤ 6. Read the article here.

Read the article or watch the video →

Updated Guideline on Brachytherapy in Prostate Cancer

May 7, 2017

The Cancer Care Ontario guideline on brachytherapy for patients with prostate cancer was updated to account for new evidence. Read the article here.

Read the article or watch the video →

15-year metastasis-free survival in men on active surveillance in The Netherlands

May 7, 2017

According to new data reported at the annual meeting of the European Association of Urology in London, active surveillance of men diagnosed with low-risk prostate cancer was not associated with an elevated risk for metastatic disease at 15 years of follow-up. Read the article here.

Read the article or watch the video →

Finding common ground on how “best” to treat localized prostate cancer, and what to tell patients

May 7, 2017

With the goals of working together more collaboratively and to provide higher quality information for patients at the time of decision-making, a prostate cancer community partnership consensus (PCPC) panel was formed among six partnering centers in the Greater Toronto Area. Read the article here.

Read the article or watch the video →